New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
08:15 EDTCTIXCellceutix enters into $10M common stock purchase agreement with Aspire Capital
Cellceutix announced that it has entered into a common stock purchase agreement with Aspire Capital Fund. Aspire has committed to purchase up to $10M of Cellceutix's common stock over the next three years at prices based on the market price at the time of each sale. Cellceutix will use the net proceeds from the Purchase Agreement to advance the Company's pipeline development, including the Phase 1 trial evaluating Kevetrin as a potential treatment for solid tumors which is currently underway at Harvard Cancer Center's Dana-Farber Cancer Institute and partner Beth Israel Deacones Medical Center; and the development of Prurisol, or KM-133, for psoriasis, where Cellceutix has begun the preparatory work necessary for a Phase 2/3 clinical trial in 2013 following guidance from the U.S. FDA for a section 505b2 designation for Prurisol.
News For CTIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 13, 2014
09:03 EDTCTIXCellceutix IND application becomes effective
Cellceutix announced that its IND has become effective and that the University of Texas MD Anderson Cancer Center has been selected as a clinical site for Cellceutix's Phase 2 trial of Brilacidin-OM as a novel treatment for oral mucositis. There are currently no drugs approved by the FDA for treating the approximately 500,000 people each year who have oral mucositis from head and neck cancers, a common and often debilitating condition affecting the mouth and pharynx as a side effect of certain cancer treatments, including chemotherapy and radiation therapy given. Cellceutix had submitted its Investigational New Drug application to the FDA in September. This is the fourth clinical trial program at Cellceutix. The three other programs are cancer, Acute Bacterial Skin and Skin Structure Infections, and psoriasis.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use